Skip to main content
. Author manuscript; available in PMC: 2012 Mar 15.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2010 Apr 8;79(4):1081–1088. doi: 10.1016/j.ijrobp.2009.12.046

Figure 2.

Figure 2

Locoregional control (LRC), disease-free survival (DFS), and Overall survival (OS) for patients with advanced head and neck cancer treated with hyperfractionated IMRT and concurrent weekly cisplatin